TY - JOUR T1 - A Single Dose Mass Balance Study of the Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Humans Using Accelerator Mass Spectrometry JF - Drug Metabolism and Disposition JO - Drug Metab Dispos SP - 1460 LP - 1467 DO - 10.1124/dmd.111.039339 VL - 39 IS - 8 AU - Richard A. Graham AU - Bert L. Lum AU - Glenn Morrison AU - Ilsung Chang AU - Karin Jorga AU - Brian Dean AU - Young G. Shin AU - Qin Yue AU - Teresa Mulder AU - Vikram Malhi AU - Minli Xie AU - Jennifer A. Low AU - Cornelis E. C. A. Hop Y1 - 2011/08/01 UR - http://dmd.aspetjournals.org/content/39/8/1460.abstract N2 - Vismodegib (GDC-0449), a small-molecule Hedgehog pathway inhibitor, was well tolerated in patients with solid tumors and showed promising efficacy in advanced basal cell carcinoma in a Phase I trial. The purpose of the study presented here was to determine routes of elimination and the extent of vismodegib metabolism, including assessment and identification of metabolites in plasma, urine, and feces. Six healthy female subjects of nonchildbearing potential were enrolled; each received a single 30-ml oral suspension containing 150 mg of vismodegib with 6.5 μg of [14C]vismodegib to yield a radioactivity dose of approximately 37 kBq (1000 nCi). Plasma, urine, and feces samples were collected over 56 days to permit sample collection for up to 5 elimination half-lives. Nonradioactive vismodegib was measured in plasma using liquid chromatographic-tandem mass spectrometry, and total radioactivity in plasma, urine, and feces was measured using accelerator mass spectrometry. Vismodegib was slowly eliminated by a combination of metabolism and excretion of parent drug, most of which was recovered in feces. The estimated excretion of the administered dose was 86.6% on average, with 82.2 and 4.43% recovered in feces and urine, respectively. Vismodegib was predominant in plasma, with concentrations representing >98% of the total circulating drug-related components. Metabolic pathways of vismodegib in humans included oxidation, glucuronidation, and uncommon pyridine ring cleavage. We conclude that vismodegib and any associated metabolic products are mainly eliminated through feces after oral administration in healthy volunteers. ER -